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Abstract 
There is a need for transplantable murine models of ovarian high grade serous carcinoma (HGSC) 
with regard to mutations in the human disease, to assist investigations of the relationships between 
tumor genotype, chemotherapy response and immune microenvironment. In addressing this need, 
we performed whole exome sequencing of ID8, the most widely-used transplantable model of 
ovarian cancer, covering 194,000 exomes at a mean depth of 400x with 90% exons sequenced 
>50x. We found no functional mutations in genes characteristic of HGSC (Trp53, Brca1, Brca2, Nf1, 
Rb1) and p53 remained transcriptionally active. Homologous recombination in ID8 remained intact 
in functional assays. Further, we found no mutations typical of clear cell carcinoma (Arid1A, 
Pik3ca), low grade serous carcinoma (Braf), endometrioid (Ctnnb1) or mucinous (Kras) 
carcinomas. Using CRISPR/Cas9 gene editing, we modeled HGSC by generating novel ID8 
derivatives that harbored single (Trp53-/-) or double (Trp53-/-;Brca2-/-) suppressor gene deletions. 
In these mutants, loss of p53 alone was sufficient to increase the growth rate of orthotopic tumors 
with significant effects observed on the immune microenvironment. Specifically, p53 loss increased 
expression of the myeloid attractant CCL and promoted the infiltration of immunosuppressive 
myeloid cell populations into primary tumors and their ascites. In Trp53-/-;Brca2-/- mutant cells, we 
documented a relative increase in sensitivity to the PARP inhibitor rucaparib and slower orthotopic 
tumor growth compared to Trp53-/- cells, with an appearance of intra-tumoral tertiary lymphoid 
structures rich in CD3+ T cells. This work validates new CRISPR-generated models of HGSC to 
investigate its biology and promote mechanism-based therapeutics discovery. 
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Introduction 
Ovarian high grade serous carcinoma (HGSC) is the commonest subtype of human ovarian cancer 
(1) and long-term survival remains poor (2). Mutation in TP53 is essentially universal (3,4), whilst 
germline mutation in BRCA1 or BRCA2 is observed in approximately 15% cases (5,6).  These 
mutations impair the ability to repair DNA double strand breaks (DSB) via homologous 
recombination (HR).  The Cancer Genome Atlas consortium suggested that HR defects may be 
present in approximately 50% HGSC through a variety of additional mechanisms, including 
somatic BRCA1/2 mutation and epigenetic loss of BRCA1 expression (4).  Another key 
development has been the finding that HGSC may arise in the fimbriae of the fallopian tube, rather 
than the ovarian surface epithelium (OSE) (7).  Early STIC (serous tubal intra-epithelial carcinoma) 
lesions in the tubal fimbriae are observed in up to 10% of women with germline BRCA1/2 
mutations undergoing prophylactic salpingo-oophorectomy (8).  Although a tubal origin of HGSC is 
widely accepted (9), STIC lesions are only seen in around half of HGSC cases (10).  Recent data 
from mouse models (11,12) and clinical HGSC samples (13) suggest that the ovary itself may still 
be crucial in the pathogenesis of HGSC, and it is possible that there could be more than one origin 
of this tumor. 
 
The absence of reliable murine models has been a major impediment in HGSC research (14).  
This is particularly important for investigation of the immune microenvironment.  The presence of 
tumor infiltrating CD8 T lymphocytes (TILs) and tertiary intra-epithelial lymphoid aggregates are 
both associated with improved prognosis in HGSC (15,16), whilst intra-tumoral 
immunosuppressive myeloid and lymphoid cells (17,18) are associated with poor prognosis.  
However, it is unclear whether or how specific genomic events in HGSC influence the immune 
microenvironment.   
 
The ID8 model, first described in 2000 (19), remains the only transplantable murine model of 
ovarian cancer routinely available.  Whole ovaries from C57Bl/6 mice were trypsin-digested, and 
the dissociated cells passaged in vitro, initially in the presence of EGF.  After approximately 20 
passages, cells lost contact inhibition, and ten separate clones were derived, of which ID8 is the 
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most widely used.  Following intra-peritoneal injection of ID8 in syngeneic mice, diffuse peritoneal 
carcinomatosis, with blood-stained ascites, develops in approximately 110 days (19).  Over 100 
publications have utilized the ID8 model, but none has characterized it in light of current 
understanding of human ovarian cancer biology. 
 
Here, we show that parental ID8 lacks mutations in Trp53, Brca1 and Brca2, and demonstrates HR 
competence in functional assays.  We have used CRISPR/Cas9 gene editing technology to 
generate single (Trp53) and double (Trp53;Brca2) knockout derivatives of ID8 and evaluated their 
utility as a model of human HGSC.  In particular, we show that loss of individual genes results in 
significant alterations in immune cell infiltration into the tumor microenvironment. 
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Materials and Methods 
Cell Culture 
ID8 cells, obtained from Dr Katherine Roby (University of Kansas Medical Center, KS), were 
cultured in DMEM supplemented with 4% fetal calf serum, 100µg/ml penicillin, 100µg/ml 
streptomycin and ITS (5 µg/ml insulin, 5µg/ml transferrin and 5ng/ml sodium selenite).  As ID8 was 
obtained directly from their original source, separate STR validation was not performed.  For 
cytotoxicity assays, cells were plated onto 24 plates (3x103 cells/well) in triplicate.  Survival was 
assessed by MTT assay (Nutlin-3) or sulphorhodamine B assay (rucaparib) after 72 hours.   
 
Next Generation Sequencing 
Whole exome sequencing and analysis was performed by Beckman Coulter Genomics (Grenoble, 
France). Full details are given in Supplementary Methods. Summary results are presented in 
Supplementary tables 1 - 3. Primary sequencing data (BAM and VCF files) are available in the 
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-
4663. 
 
Sanger sequencing 
Confirmatory Sanger sequencing of exons 2 – 9 of Trp53 was also performed on genomic DNA 
extracted from 107 parental ID8 cells in log-growth phase as well as from five separate ID8 
microdissected tumors extracted from female C57Bl/6 mice after 110 days of intraperitoneal 
growth.   
 
CRISPR/Cas9 and selection 
Two open-access software programs, CHOPCHOP (https://chopchop.rc.fas.harvard.edu/) and 
CRISPR design (http://crispr.mit.edu/) were used to design guide RNAs (gRNA) targeted to Trp53 
exon 5 and Brca2 exon 3.  Three guides were designed per gene.  Annealed oligonucleotides were 
ligated into BbsI-linearised pSpCas9(BB)-2A-Puro (PX459 (20), gifts from Feng Zhang via 
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Addgene).  Version 1 (Addgene # 48139) was employed for Trp53 deletion and version 2.0 
(Addgene # 62988) for Brca2.  All plasmids were sequenced to confirm successful ligation.   
 
4x105 ID8 cells were plated overnight in antibiotic-free medium, and transfected with 4µg PX459 
using Lipofectamine 2000, selected under puromycin (2.5 µg/ml) for 48 hours and plated onto 96 
well plates (10 cells/ml). Single cell colonies were expanded for DNA extraction, protein extraction 
and cryopreservation.  
 
PCR primers spanning potential sites of deletion were designed (Trp53: F 5’-cttccctcacattcctttcttg-
3’; R 5’-gctgttaaagtagaccctgggc-3’, Brca2: F 5’-catggagggagtcacctttg-3’; R 5’-gctctggctgtctcgaactt-
3’). Clones with large PCR deletions were selected for subsequent analysis.  Remaining clones 
were screened using the Surveyor Nuclease Assay (Integrated DNA Technology).  Mutations were 
confirmed by Sanger sequencing.  All sequence alignment was performed using MAFFT version 7 
(http://mafft.cbrc.jp/) 
 
Immunoblot and cytokine array  
15μg of total protein was electrophoresed for at 140V for 1 hour, transferred onto nitrocellulose and 
blocked in 5% non-fat milk. Antibodies used were as follows: p53 (CM5, Novacastra and Ab26, 
Abcam), β actin (Sigma A1978). Membranes were exposed on a Chemi-doc MP (Biorad) with ECL 
(β actin) and ECL prime (p53).  For array experiments, 5ml supernatant was collected from 106 
cells plated for 16 hours on a 10cm plate, and centrifuged (2000 rpm for 5 min). Mouse Cytokine 
Antibody Array C1 (C-series) was blotted according to manufacturer’s instructions (RayBiotech, Inc. 
Norcross, GA). 
 
Quantitative Reverse Transcriptase PCR 
RNA was extracted from 3x105 cells in log-growth phase, and 2µg was reverse transcribed 
(Applied Biosystems High Capacity Reverse Transcription Kit). 50ng cDNA was amplified using 
10x iTaq qRT-PCR master mix (Biorad), 20X primer probe mix in a total of 20µl under the following 
cycle parameters: 2 minutes: 50°C, 10 minutes: 95°C, 40X (15 seconds: 95°C, 1 minute 60°C ). All 
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qRT-PCR primers were purchased from Applied Biosystems and Trp53 custom made from Sigma 
Aldrich: F 5’- catcacctcactgcatggac-3’, R 5’- cttcacttgggccttcaaaa-3’, probe 5’- 
ccccaggatgttgaggagt-3’. Values were normalised to Rpl-34. 
 
γH2AX/Rad51 assay 
Cells were seeded on coverslips and treated with rucaparib (10µM for 24 hours) or irradiated 
(10Gy), permeabilized with 0.2% Triton (Sigma) in PBS for 1min, then fixed in 3% 
paraformaldehyde and 2% sucrose for 10 min.  Cells were stained with anti-γH2AX antibody 
(Millipore, Watford, UK) and co-stained with anti-Rad51 (Santa Cruz) antibody for 45 minutes at 
37oC. Cells were co-stained with DAPI. Coverslips were mounted on slides and images captured 
using a Zeiss 710 confocal microscope and foci counted using ImageJ software.  Cells were 
deemed HR competent if the number of Rad51 foci more than doubled in the presence of DNA 
double-strand break damage (≥2-fold increase in number of γH2AX foci) as previously described 
(21).   
 
In vivo experiments 
All experiments complied with the UK welfare guidelines (22) and were conducted under specific 
personal and project license authority. 5x106 cells were inoculated intraperitoneally (IP) in 6-8 
week old female C57Bl/6 mice (Charles River Laboratories, UK).  Mice were monitored regularly 
and killed upon reaching UK Home Office limits.  All decisions about animal welfare and 
experiment endpoints were made by one of us (DA) independently of main study investigators to 
prevent bias.  Ascites was collected and all visible tumor deposits dissected out.  Half of tumor 
material was snap frozen (dry ice) and half fixed in neutral-buffered 4% paraformaldehyde.  5µm 
sections from formalin-fixed paraffin-embedded tumors were stained (Dako Autostainer, Dako, UK) 
and quantified as detailed in Supplementary Methods. 
 
Ascites preparation, tumor disaggregation and flow cytometry 
Ascites was centrifuged (2200 rpm, 10 minutes) and supernatant stored at -80oC.  The cell pellet 
was treated with red blood cell lysis buffer (Sigma Aldrich, UK – 5 minutes, room temperature), re-
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suspended in 10ml PBS, re-centrifuged, and stored at -80oC in FBS/10% DMSO.  Solid tumor 
deposits in ice cold PBS/protease inhibitor solution were dissected into pieces less than 1mm 
diameter using a scalpel and digested at 37°C for 30 minutes (0.012% w/v collagenase type XI, 
0.012% w/v dispase, 0.25% Trypsin in 0.1% BSA in RPMI.) 10ml of 0.1% BSA/RPMI was added 
and the tubes shaken vigorously followed by 100µm filtration. Cells were centrifuged for 5 minutes 
at 1500 rpm, re-suspended in PBS containing 5% FBS, and then counted.  Flow cytometry and 
gating strategies are presented in Supplementary Methods. 
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Results 
Characterization of parental ID8 in vitro and in vivo. 
To assess the genomic landscape of ID8, we undertook whole exome sequencing, covering 
approximately 194,000 exons at a mean depth of 400x with 90% exons sequenced >50x.  
Approximately 6000 variants were identified, the vast majority of which were non-functional.  
Functional alterations (non-synonymous coding, stop-gain and frameshift) were identified in 
approximately 100 genes, the large majority of which were non-synonymous coding (See 
Supplementary Tables 1-3 for summary and list of all functional alterations).  However, we were 
unable to identify any functional mutations in genes characteristic of HGSC (Trp53, Brca1, Brca2, 
Nf1, Rb1) and the absence of Trp53 mutations was confirmed by Sanger sequencing (data not 
shown).  In addition, mutations typical of clear cell (Arid1A, Pik3ca), low grade serous (Braf), 
endometrioid (Ctnnb1) and mucinous (Kras) carcinomas were also notably absent.  We did identify 
a mutation in Adamts3 (c.1089C>T; pV199I) – a recent analysis of TCGA data identified that 
mutations in ADAMTS genes were associated with platinum sensitivity as well as improved 
progression-free and overall survival in HGSC (23).  In addition, mutation in Gabra6 (c.347T>G; 
pE22D) was identified. GABRA6 was one of the genes mutated at statistically significant frequency 
in TCGA analysis - however, transcription was absent in all TCGA tumors, suggesting that 
GABRA6 mutation is of minimal clinical relevance (4). 
 
Given the centrality of TP53 mutations in HGSC, we also assessed p53 function in ID8.  There was 
a robust increase in p53 protein following treatment with cisplatin and the MDM2 inhibitor Nutlin-3 
(Fig. 1A), with marked increases in Cdkn1A (p21) transcription within 4 hours of cisplatin treatment 
(Fig. 1B), indicating that p53 remains transcriptionally active.  Sanger sequencing of intraperitoneal 
ID8 tumors showed no Trp53 mutation in any tumor, including common hotspot mutations sites 
(R172, Y217, R245, R270 – Fig. 1C), whilst immunohistochemistry (IHC) confirmed a wild-type 
pattern of p53 expression (Fig. 1D).  IHC examination of typical HGSC markers indicated that 
tumors were strongly and diffusely positive for WT1, but negative for Pax8 (Fig. 1D). 
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The whole exome sequencing data identified no functional abnormalities in Brca1, Brca2 or other 
HR genes.  We confirmed that parental ID8 cells were able to form Rad51 foci in response to DNA 
double-strand break damage induced by irradiation as well as the PARP inhibitor rucaparib (Fig. 
1E), and fulfilled the criteria of competent HR as previously described (21).  Together, these data 
suggest that parental ID8 is poorly representative of human HGSC. 
 
CRISPR/Cas9-mediated Trp53 gene editing 
Three separate guide RNA (gRNA) constructs targeted to exon 5 of Trp53 (Fig. 2A), were cloned 
into the PX450 plasmid.  Following transfection and screening (Fig. 2B, C), clones were derived 
from all three guides (F3 – guide G; A2 – guide K; C7 and M20 – guide R), all of which contained 
bi-allelic deletions in Trp53 exon 5 (Fig. S1), ranging from 4bp (clone M20) to 280 bp (clone A2).  
All four null clones showed absent basal p53 expression by immunoblot (Fig. 2D), with significantly 
reduced basal transcription of Trp53 (Fig. 2E), Cdkn1a and Bax (Fig. 2F).  There was also no 
increase in p53 expression following treatment with cisplatin or Nutlin-3 (Fig. 2G), nor an increase 
in Cdkn1a transcription following cisplatin (Fig. 2H).  Finally, there was a significant reduction in 
cell death induced by Nutlin-3 in all four clones compared to parental ID8 (Fig. 2I).  These results 
collectively indicate that all four Trp53-/- clones are functionally p53 deficient.  We also isolated 
control clones that had been exposed to CRISPR plasmids (both empty PX459 and PX459 
encoding Trp53 gRNA) but did not contain any Trp53 mutation on sequencing.  These cells 
retained p53 transcriptional activity that was indistinguishable from parental ID8 (Fig. S2).   
 
We then assessed intra-peritoneal growth of the Trp53-/- clones.  Following intra-peritoneal 
injection into female C57Bl/6 mice, there was a highly significant reduction in time to reach pre-
defined humane endpoints with all four clones. Median survival time ranged from 42-57 days (Fig. 
3A), compared with 101 days for mice bearing either parental ID8 or CRISPR control cells 
(p<0.0001 for all clones compared to both parental ID8 and CRISPR controls).  There was no 
difference in volume of ascites between parental ID8, CRISPR control or Trp53-/- tumors (Fig. 3B).  
Macroscopically, the patterns of growth and spread within the peritoneal cavity were similar, 
although there was some evidence of increased numbers of miliary deposits on the peritoneum 
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and diaphragm in Trp53-/- tumors (Fig. 3C).  By immunohistochemistry, we confirmed absence of 
p53 expression in Trp53-/- tumors (Fig. 3D). Trp53-/- tumors retained strong positivity for WT1, but 
remained negative for Pax8 (Fig. 3E).  We also observed significant increases in Ki67 expression 
in Trp53-/- tumors (Fig. 3F), consistent with their more rapid intra-peritoneal growth.   
 
Generation of double Trp53-/-;Brca2-/- mutants 
We next targeted exon 3 of Brca2, which encodes the PALB2 binding domain (Fig. 4A).  Using the 
F3 Trp53-/- clone, we generated three separate double Trp53-/-;Brca2-/- clones (1.4, 2.14 and 3.15), 
each derived from a different guide, and each with distinct deletions (Fig. S3).  All three Trp53-/-
;Brca2-/- clones fulfilled the criteria for defective HR (21) (Fig. 4B) and lost the ability to form Rad51 
foci in response to irradiation (Fig. 4C, Fig. S4).  In addition, all clones were significantly more 
sensitive to PARP inhibitor-mediated cytotoxicity (Fig. 4D).  By contrast, control cells (Trp53-/- cells 
exposed to PX459 encoding Brca2 gRNA but with no Brca2 deletion) had the same sensitivity to 
rucaparib as parental ID8 and F3 Trp53-/-, and were HR competent by Rad51 assay (data not 
shown).   
 
We also assessed intraperitoneal growth of Trp53-/-;Brca2-/- clones.  When analyzed individually, 
there was no difference in mouse survival between Trp53-/- F3 tumors and any of the double null 
tumors (Fig. 4E).  However, when analyzed collectively, there was a small, but significant, increase 
in survival: mice bearing Trp53-/-;Brca2-/- tumors survived 10 days longer than Trp53-/- F3 tumors 
(57 vs 47 days; p<0.01. Fig. S5).  In addition, mice had significantly lower ascites volumes than 
either parental or Trp53-/- tumors (Fig. 4F).  There were large diaphragmatic and peritoneal 
deposits, and ascites was consistently less hemorrhagic (Fig. S6).  Ki67 histoscores were 
significantly higher than ID8 parental tumors (not shown) but not significantly different to those 
seen in Trp53-/- (Fig. 4G). 
 
Tumor microenvironment 
To investigate the utility of our new ID8 derivatives to study the relationship between specific 
mutations within malignant cells and the tumor microenvironment, we first stained tumors for the 
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presence of T lymphocytes (both CD3 and CD8) and macrophages (F4/80). Intra-epithelial CD3+ 
and CD8+ cells were both generally sparse, with no significant differences between any of the 
tumor genotypes (Fig. 5A, 5B).  However, we observed the presence of lymphoid aggregates 
within Trp53-/-;Brca2-/- tumors that were absent from both parental ID8 and Trp53-/- tumors (Fig. 5C, 
Fig. S7, 8).  These aggregates were composed predominantly of CD3+ cells, although CD8+ 
populations were visible at the periphery (Fig. S9).  We also observed striking and significant 
increases in macrophage infiltration in Trp53-/- tumors (Fig. 5D, Fig. S10).  Macrophage infiltration 
was more variable in Trp53-/-;Brca2-/- tumors – median histoscore was greater than in ID8 parental 
tumors but lower than in Trp53-/- tumors, although neither difference was statistically significant 
(Fig. 5D).   
 
We next investigated the specific role of p53 loss upon myeloid populations.  Immunoblot array 
showed marked increases in the monocyte chemoattractant CCL2, and, to a lesser extent, CCL5 
and sTNFR1 in conditioned medium from Trp53-/- cells (Fig. 6A, Fig. S11). Immunophenotyping of 
disaggregated solid tumor deposits (Fig. 6B, Fig. S12) and ascites (Fig. 6C, Fig. S12) showed 
significant increases in CD11b+ populations in Trp53-/- tumors compared to Trp53 wild-type.  
Monocytic myeloid-derived suppressor cells (defined as CD11b+Ly6C+Ly6G-) were the 
predominant myeloid population in both tumor and ascites compared to polymorphonuclear (PMN) 
MDSC populations (CD11b+Ly6C+Ly6G+).  Consistent with IHC, we found significantly more 
F4/80 positive cells within Trp53-/- ascites, although the proportions of iNOS+ and CD206+ cells did 
not alter significantly between the two genotypes (Fig. 6D, Fig. S13 and S14).   
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Discussion  
Here we show that ID8, a widely used murine model of ovarian carcinoma, is poorly representative 
of HGSC, with a conspicuous absence of mutations in genes associated with the human disease, 
and evidence of functional p53 activity.  The overall mutational burden in ID8 is low (functional 
variants in only 100 genes in 49MB of sequenced DNA), which concurs with very recent data from 
ID8-G7, a subline of ID8 that has been passaged in vivo (24).  We did not observe activating 
mutations in common oncogenes (e.g. Kras, Nras, Myc, Egfr, Pik3ca) that may drive 
carcinogenesis in parental ID8 cells, but we have not undertaken copy number analyses, and thus 
cannot exclude the presence of an oncogenic amplification.  
  
Using CRISPR/Cas9 gene editing, we generated sublines of ID8 bearing loss-of-function deletions 
in Trp53 and Brca2, and demonstrate that these alter tumor growth in the peritoneal cavity.  In 
preliminary experiments, we also show that single gene mutations can alter the tumor 
microenvironment, with a significant increase in immunosuppressive myeloid populations within 
tumor and ascites upon loss of p53 expression, as well as the appearance of intra-epithelial 
lymphoid aggregates in tumors lacking both p53 and Brca2. 
 
Genetically engineered mouse models of HGSC have been difficult to generate (25).  Recently, 
two HGSC models were described: the Drapkin lab utilized the Pax8 promoter to drive Cre-
mediated recombination of Trp53 and Pten with Brca1 or Brca2 in mouse fallopian tube secretory 
epithelium.  This resulted in development of STIC lesions, and subsequent invasive tumors in the 
ovary and peritoneal cavity within 20 weeks (26).  By morphology and immunohistochemistry, the 
tumors resembled human HGSC, but no ascites was observed and all Pten-/- mice developed 
endometrial lesions (hyperplasia, dysplasia or carcinoma).  In addition, no transplantable cell lines 
have been described from these mice.  A second fallopian tube model has been described, with 
SV40 large T-antigen under the control of the Ovgp-1 promoter (27,28).  Again, STIC-like lesions 
with p53 signatures were described, as well as invasive tumors within the ovary.  However, no 
peritoneal dissemination or ascites were seen, and, again, no lines that can be readily transplanted 
into non-transgenic mice have been described.  Both of these models are undoubtedly of great 
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importance.  However, we believe that a transplantable model, based on a single genetic 
background (C57Bl/6), which recapitulates disseminated peritoneal disease with ascites and in 
which multiple genotypes can potentially be rapidly investigated in parallel, is an important adjunct 
to transgenic models. 
 
One potential criticism of our models is that they arise from a single cell line.  Although other 
murine ovarian cancer cell lines have been described (29), they derive from chimeric SV40 T-Ag 
animals, and thus cannot be transplanted into non-transgenic animals, which significantly reduces 
their utility. ID8 remains the only murine line derived from a single non-transgenic strain from which 
to base these models.  A second potential criticism is the cell of origin of ID8 itself.  In the original 
description of ID8 (19), whole mouse ovaries were trypsinized with the aim of removing the OSE 
layer, but the exact cell of origin of ID8 is unclear.  Although the fallopian tube is undoubtedly the 
originating site of many HGSC, a potential ovarian origin is possible for a subset of these tumors 
(13).  In addition, data from the Drapkin lab model indicated that oophorectomy reduced peritoneal 
dissemination, suggesting that the ovary plays a role in promoting metastatic spread of fallopian 
tube lesions (26).  Thus, an OSE origin of ID8 does not preclude the applicability of our new cells 
as a model of HGSC, and our tumors do express some typical HGSC markers (e.g. WT1).  
However, the absence of Pax8 staining strongly suggests that ID8 is not of fallopian tube secretory 
origin.  PAX8 staining is used in the diagnosis of HGSC and is usually strongly positive, although 
this is not universal (30).  Therefore, the absence of Pax8 in our ID8 models is important to note, 
but is not a barrier to their use in HGSC research.   
 
Although CRISPR/Cas9 gene editing is an extremely powerful tool, off-target effects can occur  
(31,32), which are difficult to quantify precisely in any given model without whole genome 
sequencing.  Here, we used multiple different guides and selected at least one clone per guide.  In 
addition, we utilized appropriate negative controls (cells exposed to CRISPR plasmid transfection 
but which do not contain mutations in target gene). The uniform phenotypes observed in each of 
our models suggest strongly that any off-target effects are not significant.   
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Finally, we have undertaken preliminary experiments to investigate the link between tumor-specific 
mutations and immune composition in the microenvironment.  Here, we show that loss of p53 
increases CCL2 expression and induces marked increases in immunosuppressive myeloid 
populations both within solid tumor deposits and ascites.  CCL2 is a critical chemokine for 
attraction of monocyte populations; wild-type p53 can suppress CCL2 expression via direct binding 
to the CCL2 5’UTR (33) and can reduce CCL2-induced xenograft growth (34).  In Trp53-/- tumors, 
there appeared to be a bias towards monocyte MDSC populations, which have been characterized 
as more immunosuppressive than PMN MDSC in tumor-bearing mice (35).  Intriguingly, we also 
observed aggregates of lymphoid cells in tumors lacking both p53 and Brca2. The structures 
contained hundreds of cells, which were predominantly CD3+ but CD8-.  Four different types of 
lymphoid aggregates in HGSC were recently described, the largest of which resembled activated 
lymph nodes (16), and which contain a variety of T and B cell lineages, including plasma cells.  
The presence of plasma cells was associated with expression of two genes, IGJ and TNFRSF17, 
but was independent of mutation in BRCA1 or BRCA2.  Our preliminary data suggest that loss of 
Brca2 and p53 can lead to formation of tertiary lymphoid aggregates, but further work, including 
gene expression analysis and further flow cytometry, will be required to elucidate this relationship.  
It is not clear whether these microenvironmental changes explain why loss of Brca2 and p53 
function results in slower intraperitoneal growth compared to p53 loss alone. Ki67 staining 
suggests that there is no significant reduction in proliferation in the Trp53-/-;Brca2-/- tumors, 
suggesting that non-cell autonomous factors may be contributing.  Certainly, in patients with HGSC, 
BRCA2 mutation and the presence of intra-tumoral lymphocytes (15) are both associated with 
longer overall survival (36), although the precise mechanisms for this remain unclear.   
 
In summary, we have used gene editing technology to generate transplantable murine ovarian 
cancer cell lines that recapitulate critical mutations in human HGSC.  Our results suggest that our 
ID8 models may act as an important tool, alongside GEMM and primary patient material, in 
understanding the complexities of HGSC biology.  Further mutants are under construction, and all 
our ID8 derivatives are freely available to other researchers.  
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Figure Legends 
Figure 1. ID8 retains wild-type p53 function and demonstrates competent homologous 
recombination 
A. Expression of p53 was assessed in ID8 cells following treatment for up to 8 hours with 10 µM 
cisplatin (left) or 10 µM Nutlin-3 (right) 
B. Transcription of p53 target Cdkn1a in ID8 cells following treatment for up to 8 hours with 10 µM 
cisplatin was assessed by quantitative reverse-transcriptase PCR, normalised to Rpl34.  Data 
represent mean +/- s.d. (n=3) plotted relative to untreated cells (t = 0 hrs). 
C. Representative chromatograms of Sanger sequencing of p53 from parental ID8 tumors 
harvested after 110 days intraperitoneal growth in female C57Bl/6 mice, demonstrating no 
mutations at critical hotspot mutations sites at residues 172, 217, 245 and 270 – the equivalent 
human codons are shown in parentheses below. 
D. ID8 tumors, fixed in 4% neutral-buffered formalin, were stained for p53, WT1 and PAX8.  Bars 
represent 100 µm. 
E. ID8 cells were irradiated (10Gy) or treated with rucaparib (10µM for 24h), fixed and stained for 
γH2AX and RAD51, and counterstained with DAPI.  RAD51 foci were counted in up to 30 
untreated and rucaparib-treated cells. Bars represented mean (+/- s.d.) RAD51 foci per cell; dotted 
line represents two-fold increase in RAD51 foci/cell relative to untreated cells, suggestive of 
functional homologous recombination (21). 
 
Figure 2.  Generation and evaluation of Trp53-/- ID8 cells using CRISPR/Cas9. 
A. Design of three gRNA sequences, targeted to exon 5 of Trp53 (upper).  Nucleotides in red 
represent PAM sequences. Schematic representation of p53 protein (lower).  Numbers represent 
amino acid positions. Amino acids encoded by exon 5 are marked in red. 
B. Representative PCR of 1kb region spanning Trp53 exon 5 from genomic DNA extracted from 
ID8 and 15 single cell clones transfected with PX459 expressing gRNA K.  Clones with 
demonstrable deletions are marked *.   
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C. Representative Surveyor Nuclease Assay, performed on ID8 and 11 single cell clones 
transfected with PX459 expressing Trp53 gRNA K as described in Material and Methods.  Clones 
with mismatch suggestive of nucleotide deletion are marked *. 
D. Expression of p53 was assessed in parental ID8 and four Trp53-/- clones by immunoblot 
E. Transcription of Trp53 was assessed in parental ID8 and four Trp53-/- clones by quantitative 
reverse-transcriptase PCR, normalised to Rpl34.  Bars represent mean +/- s.d. (n=3) plotted 
relative to parental ID8. 
F. Transcription of p53 target genes Cdkn1a and Bax was assessed in parental ID8 and Trp53-/- 
clones by quantitative reverse-transcriptase PCR, normalised to Rpl34.  Bars represent mean +/- 
s.d. (n=3) plotted relative to parental ID8. 
G. Expression of p53 in ID8 and Trp53-/- clones before and after cisplatin (10 µM, 8 hours – left) 
and Nutlin-3 (10 µM, 2 hours – right). 
H. Fold-increase in Cdkn1a transcription in ID8 and Trp53-/- clones following cisplatin treatment (10 
µM, 8 hours).  Bars represent mean +/- s.d. (n=3), and dotted line represents baseline transcription 
in each cell population. 
I. ID8 and Trp53-/- clones were treated with 10 µM Nutlin-3, and cell survival assessed by MTT 
after 72 hours.  Bars represent cell survival (mean +/- s.d., n=3) relative to untreated cells. 
 
Figure 3.  Loss of p53 increases rate of intraperitoneal growth of ID8 tumors. 
5x106 cells were injected intraperitoneally into female C57Bl/6 mice in groups of 6. Mice were killed 
when they reached humane endpoints.  Ascites was taken from all mice and measured. Each point 
on histoscore plot represents mean score for multiple deposits (median 5, range 1 – 17) per animal 
normalised to tumor area. 
A. Loss of p53 significantly increases rate of intraperitoneal growth (p<0.0001 for all Trp53-/- clones 
compared to both parental ID8 and CRISPR control cells). Data from four ID8 parental groups 
(total n=24) and two groups each of CRISPR control and Trp53-/- F3 (total n = 12) are plotted. 
B. Loss of p53 does not alter volume of ascites at humane endpoint. 
C. Loss of p53 increases number of tumor deposits on peritoneal (white box) and sub-
diaphragmatic (arrows) surfaces.  Representative images from at least mice per genotype. 
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D. Loss of p53 expression was confirmed by quantitative IHC in Trp53-/- tumors.  **;p<0.01 
E. No change in WT1 and PAX8 expression following p53 loss. 
F. Loss of p53 expression significantly increases intraperitoneal tumor proliferation, as measured 
by Ki67 staining. ****;p<0.0001. 
 
Figure 4.  Generation and evaluation of Trp53-/-;Brca2-/- ID8 cells using CRISPR/Cas9. 
A. Design of three gRNA sequences, targeted to exon 3 of Brca2 (upper).  Nucleotides in red 
represent PAM sequences.  Schematic representation of Brca2 protein (lower).  Numbers 
represent amino acid positions.  OB – oligonucleotide binding domain; NES – nuclear export signal.  
Amino acids encoded by exon 3 are marked in red.  
B. Parental ID8, Trp53-/- cell line F3 and three Trp53-/-;Brca2-/- cells were treated with rucaparib 
(10µM), fixed and stained for γH2AX and RAD51, and counterstained with DAPI.  Representative 
confocal microscopy images are presented (upper panels). RAD51 foci were counted in up to 30 
untreated and rucaparib-treated cells. Bars represented mean (+/- s.d.) foci per cell relative to 
untreated cell; dotted line represents two-fold increase in foci/cell relative to untreated cells. 
C. Trp53-/- cell line F3 andTrp53-/-;Brca2-/- 3.15 cells were irradiated (10Gy), fixed and stained for 
γH2AX and RAD51, and counterstained with DAPI.   
D. Trp53-/-;Brca2-/- cells are significantly more sensitive to PARP inhibitor-induced cytotoxicity than 
either parental ID8 or Trp53-/- cell line F3.  Each dot represents IC50 value from a single experiment 
performed in triplicate.  Bars represent median IC50 for three separate experiments. 
E. 5x106 cells were injected intraperitoneally into female C57Bl/6 mice in groups of 6.  Mice were 
killed when they reached humane endpoints.  Ascites was taken from all mice and measured.  F3 
CRISPR control cells are Trp53-/- F3 cells exposed to PX459 encoding Brca2 gRNA (Guide 1), but 
which contain no deletion in Brca2 on sequencing.   
F. Loss of Brca2 and p53 reduces volume of ascites compared to loss of p53 alone. **;p<0.01. 
G. Additional loss of Brca2 expression does not significantly alter intraperitoneal tumor proliferation, 
as measured by Ki67 staining.  Bars on IHC images represent 100 µm.  Each dot represents mean 
histoscore for multiple deposits (median 5, range 1 – 17) per animal, normalised to tumor area. 
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Figure 5.  Loss of p53 and Brca2 expression alters immune cell infiltration in ID8 tumors 
Formalin-fixed, paraffin-embedded tumors from all three genotypes (parental ID8, Trp53-/- and 
Trp53-/-;Brca2-/-) were stained for CD3 (A) and CD8 (B).  The number of intra-epithelial lymphoid 
aggregates, defined as an area >0.1mm2, was counted in tumors from all three genotypes (C).  No 
aggregates were identified in ID8 and Trp53-/- tumors.  Bar represents median.  *:p<0.05. 
Tumors were also stained for F4/80 (D).  All bars represent 100 µm.  Intensity of expression was 
quantified as detailed in Materials and Methods.  Each dot represents mean histoscore for multiple 
deposits per animal, normalised to tumor area.  *;p<0.05. 
 
Figure 6.  Loss of p53 expression increases CCL2 expression and induces 
immunosuppressive myeloid cell infiltration in tumor and ascites 
A. Expression of chemokines in conditioned medium was assessed using immunoblot array.  See 
Fig. S9 for complete array layout. 
B, C and D. Disaggregated whole tumor deposits (B) and ascites cells (C, D) were assessed by 
flow cytometry for CD4, CD8, CD11b, Ly6G, Ly6C, F4/80, CD206 and iNOS.  Each dot represents 
a single tumor deposit (minimum three deposits/mouse) or ascites sample.  Bars represent mean 
+/- s.d. Trp53+/+ populations include ID8 parental and CRISPR control cells lacking any Trp53 
mutation.  ***;p<0.001, **;p<0.01, *;p<0.05. 
 
 






